$121 Million is the total value of Saturn V Capital Management LP's 19 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $11,336,501 | – | 623,819 | +100.0% | 9.41% | – |
| New | 2SEVENTY BIO INC | $9,885,521 | – | 684,996 | +100.0% | 8.20% | – | |
| APLS | New | APELLIS PHARMACEUTICALS INC | $9,414,319 | – | 212,329 | +100.0% | 7.81% | – |
| ARQT | New | ARCUTIS BIOTHERAPEUTICS INC | $8,787,113 | – | 487,179 | +100.0% | 7.29% | – |
| CYTK | New | CYTOKINETICS INC | $7,973,579 | – | 196,982 | +100.0% | 6.62% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $7,953,761 | – | 68,404 | +100.0% | 6.60% | – |
| MORF | New | MORPHIC HLDG INC | $7,373,162 | – | 269,827 | +100.0% | 6.12% | – |
| ITOS | New | ITEOS THERAPEUTICS INC | $7,027,867 | – | 342,071 | +100.0% | 5.83% | – |
| ALBO | New | ALBIREO PHARMA INC | $6,864,695 | – | 341,827 | +100.0% | 5.70% | – |
| KDNY | New | CHINOOK THERAPEUTICS INC | $6,728,298 | – | 423,177 | +100.0% | 5.58% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $6,697,459 | – | 719,937 | +100.0% | 5.56% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $5,718,432 | – | 1,611,778 | +100.0% | 4.74% | – |
| HZNP | New | HORIZON THERAPEUTICS PLC | $5,681,051 | – | 69,170 | +100.0% | 4.71% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $5,367,609 | – | 156,085 | +100.0% | 4.45% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $4,893,334 | – | 566,179 | +100.0% | 4.06% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $3,751,030 | – | 340,163 | +100.0% | 3.11% | – |
| BIIB | New | BIOGEN INC | $2,169,987 | – | 7,660 | +100.0% | 1.80% | – |
| New | ASTRIA THERAPEUTICS INC | $1,556,562 | – | 169,493 | +100.0% | 1.29% | – | |
| TBPH | New | THERAVANCE BIOPHARMA INC | $1,334,342 | – | 141,339 | +100.0% | 1.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CRINETICS PHARMACEUTICALS IN | 4 | Q3 2023 | 14.0% |
| CYMABAY THERAPEUTICS INC | 4 | Q3 2023 | 10.6% |
| CYTOKINETICS INC | 4 | Q3 2023 | 7.4% |
| KALVISTA PHARMACEUTICALS INC | 4 | Q3 2023 | 7.3% |
| HORIZON THERAPEUTICS PUB L | 4 | Q3 2023 | 8.1% |
| BIOGEN INC(NSM) | 4 | Q3 2023 | 7.8% |
| ASCENDIS PHARMA A/S - ADR | 4 | Q3 2023 | 6.6% |
| ITEOS THERAPEUTICS INC | 4 | Q3 2023 | 5.8% |
| MORPHIC HOLDING INC | 4 | Q3 2023 | 6.9% |
| BIOCRYST PHARMACEUTICALS INC | 4 | Q3 2023 | 7.2% |
View Saturn V Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-09 |
View Saturn V Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.